SCHEMBL3713256

SCHEMBL3713256

O=Cc1cccnc1NC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.47
TRIM33 Q9UPN9 1/20 0.47
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
KMT2A Q03164 4/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
KDM4E B2RXH2 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HSP90AA1 P07900 1/20 0.40
IDO1 P14902 1/20 0.40
DHODH Q02127 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954898 0.84 TRIM24 (0.46) TRIM24TRIM33RAB9ANPC1HTT
SCHEMBL1375331 0.80 L3MBTL1 (0.45) TRIM24TRIM33RAB9ANPC1HTT
SCHEMBL28110815 0.80 TRIM24 (0.42) TRIM24TRIM33RAB9ANPC1HTT
SCHEMBL2211898 0.80 CYP1A2 (0.48) RAB9ANPC1HTTMAPTALDH1A1
SCHEMBL306384 0.77 METAP1 (0.44) TRIM24TRIM33RAB9AHTTMAPT
SCHEMBL29956983 0.77 POLB (0.53) RAB9ANPC1ATMMAPTALDH1A1
SCHEMBL1652624 0.76 NPC1 (0.61) RAB9ANPC1HTTATMKMT2A
SCHEMBL31023942 0.76 TRIM24 (0.52) TRIM24TRIM33RAB9ANPC1HTT
SCHEMBL1376029 0.76 TRIM24 (0.52) TRIM24TRIM33RAB9ANPC1HTT
SCHEMBL1558713 0.76 RAB9A (0.70) RAB9ANPC1HTTATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771351-B2 Wnt signaling inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-09-26 US disclosed
US-20160168125-A1 WNT SIGNALING INHIBITOR KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-06-16 US disclosed
EP-3028703-A1 Wnt SIGNALING INHIBITOR Kyowa Hakko Kirin Co., Ltd. (JP) 2016-06-08 EP disclosed
WO-2013064231-A1 SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) PHENEX PHARMACEUTICALS AG (DE) 2013-05-10 WO disclosed
EP-2391623-A1 INHIBITORS OF AKT ACTIVITY Merck Sharp & Dohme Corp. (US) 2011-12-07 EP disclosed
WO-2010088177-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME CORP. (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168125-A1 WNT SIGNALING INHIBITOR WNT3A, WNT1, WNT3 TRIM24 2875/4885TRIM33 4110/4885RAB9A 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.